🔗 Share this article

While America continues making historic revisions to its vaccination recommendations, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by casting doubt on coronavirus vaccinations during the global health crisis and has concentrated on potential fatalities following Covid vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Vaccine Schedule

Public health authorities were set to reveal sweeping changes to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would put the US out of alignment with much of the international standard with insufficient data for benefit. The planned update has been pushed back until the next year.

Instead of the top vaccines chief, Tracy Beth Høeg is listed to present at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

Consolidating Power at the Regulatory Body

This interim role might represent a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood vaccine recommendations in the US in order to be more in line with the Danish model, a nation with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

So far statements, she has kept her attention on vaccines – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

The appointee has no obvious experience in pharmaceutical research, approval processes or management, which has been typical for previous directors of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“It seems she lacks to have the necessary background” for running the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a scientific study. She is not versed in running a sizeable institution. She is not an expert in industry regulation.”

Previous heads of CBER would “grasp laws and regulations and the research of drug development”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that previous people who led the center have had.”

This division has an enormous portfolio at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and more, and all of those need to be managed,” Woodcock explained. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant management aspect to the position, which supervises over 5,000 staff members. “It’s a enormous administrative position, if you do it right,” she concluded.

Response and Controversial Programs

Regarding inquiries about Høeg’s credentials and whether this assignment indicates greater collaboration among regulatory chiefs on immunizations, a press secretary responded that the “questions are based on incorrect premises”.

“This background is consistent with the responsibilities of her position,” the official stated, citing the months Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's new priority voucher program, a contentious rapid medication authorization process that apparently concerned her predecessors. “How are these drugs being selected for this expedited pathway? Who is making the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

Broadly speaking, he stated, “the agency looks to be trending towards laxer oversight of pharmaceuticals, aside from shots.”

Documented History on Immunizations

Concerning vaccines, Høeg has a clearer, if troubling, track record, critics have noted. She released a research paper using unverified public submissions to determine the incidence of myocarditis after Covid vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming government featured revising guidelines for recently developed shots and ending “optional” immunizations, she remarked post-election on a audio program. At the FDA, Høeg has allegedly floated the idea of excluding teenage boys from receiving COVID-19 vaccinations.

“She’s an thorough true believer who begins with her conclusions and works backwards to fit the data in a extremely disingenuous, untruthful manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|